卵巢癌腹腔热灌注化疗的研究进展

李 楠楠, 刘 惠琴, 云 翠兰, 张 越美, 杨 旭
内蒙古医科大学 内蒙古自治区 010000

摘要

目的：卵巢癌是最常见的妇科恶性肿瘤，其发病率在女性恶性肿瘤中居第三位，病死率居妇科恶性肿瘤之首，此病发现时多数已为中晚期，且大多数晚期卵巢癌患者常伴随腹腔转移及腹腔积液，严重影响了临床治疗效果。常规的手术与化疗相结合的方式无法保证化疗药物的最高血药浓度作用时间,不能达到明显延长生存期的目的。因此腹腔热灌注化疗作为原有治疗方法的另一种选择，越来越受到临床的关注。本文对腹腔热灌注化疗在晚期卵巢癌的应用做一综述，为临床治疗提供指导。

关键词

腹腔热灌注化疗；卵巢癌；临床疗效

参考

[1] Chen Dongying,Wang Wuliang.Clinical efficacy analysis of peritoneal heat perfusion combined with intravenous chemotherapy in patients after ovarian cancer [J]. The Electronic Journal of Modern Medicine and Health Research, 2022,6 (18): 68-71.[2] Kitayama J, Ishigami H, Yamaguchi H and Watanabe T: Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) combined with oral tegafur/gimeracil/oteracil potassium (S-1) for gastric cancer with peritoneal metastasis. Eur J Surg Oncol 40: S34, 2014.[3] Ceelen W, Braet H, van Ramshorst G, Willaert W, Remaut K. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion.Expert Opin Drug Deliv. 2020;17(4):511-522. doi:10.1080/17425247.2020.1736551[4] Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am. 2012;21(4):645-663. doi:10.1016/j.soc.2012.07.007[5] van den Tempel N, Horsman MR, Kanaar R. Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. Int J Hyperthermia. 2016;32(4):446-454. doi:10.3109/02656736. 2016.1157216[6] Didelot C, Lanneau D, Brunet M, et al. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins.Curr Med Chem. 2007;14(27):2839-2847. doi:10.2174/092986707782360079[7] Zunino B, Rubio-Patiño C, Villa E, et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene. 2016;35(2):261-268. doi:10.1038/onc.2015.82[8] Mallory M, Gogineni E, Jones GC, Greer L, Simone CB 2nd. Therapeutic hyperthermia: The old, the new, and the upcoming. Crit Rev Oncol Hematol. 2016;97:56-64. doi:10.1016/j.critrevonc.2015.08.003